Granules India gets USFDA’s nod for ADHD generic
Granules India's subsidiary, GPI, receives USFDA approval for Lisdexamfetamine Dimesylate Capsules, expanding ADHD treatment ...
india-briefing.com11h
Why India’s Pharmaceutical Industry Remains Poised for Growth in 2025
India's pharmaceutical industry is set for growth, driven by strong market players, global reputation, and evolving trends.
Granules India Limited receives final approval from USFDA for its new drug
Lisdexamfetamine Dimesylate is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in adults and ...
Your Story2d
Navigating beauty regulations: How Indian makeup and skincare brands ensure compliance
In India’s rapidly growing beauty sector, compliance with regulatory standards is not just a legal necessity but also a ...
India Today on MSN6d
India approves living drug to treat blood cancer: All about Qartemi and how it works
The second indigenous CAR-T cell therapy, Qartemi, has been approved by India's drug regulator. Qartemi is a "living drug" ...
Indian drugmaker Dr Reddy's says it is 'optimistic' about Trump administration
Indian generic drugmaker Dr Reddy's Laboratories on Thursday said it was optimistic about the Donald Trump administration, as it believes the country would have an edge amid tensions between the ...